CTAG1B and ovarian carcinoma: The mice were treated with either 24.4 mg/kg guadecitabine or vehicle every fifth day for a total of four times, as this dosing strategy was effective for induction of MAGE and NY-ESO-1 CT antigens in in vivo models of leukemia and ovarian cancer (34, 35).